S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY. (23rd June 2022) - Sehgal, A.; Hoda, D.; Riedell, P. A.; Ghosh, N.; Hamadani, M.; Hildebrandt, G. C.; Godwin, J. E.; Reagan, P.; Wagner-Johnston, N.; Essell, J.; Nath, R.; Solomon, S. R.; et al.